Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade® in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis

• Published in: Advances in therapy Vol. 40; no. 3; pp. 1005 - 1018
• Main Authors: Su, Yin, Li, Jing, Wang, Chenguang, Zhang, Xunmin, Hou, Sheng, Guo, Huaizu, Deng, Chenhui, Ou, Lun, Wang, Jinwei
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.03.2023
• Subjects: Albumins - therapeutic use; Antibodies, Monoclonal - therapeutic use; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Biosimilar Pharmaceuticals - therapeutic use; Cardiology; Endocrinology; Healthy Volunteers; Humans; Infliximab - therapeutic use; Internal Medicine; Male; Medicine; Medicine & Public Health; NCT; NCT03478111; NCT04779892; Oncology; Original Research; Pharmacology/Toxicology; Rheumatology; Infliximab; Rheumatoid arthritis; Biosimilar; Population pharmacokinetic

Introduction CMAB008 is a monoclonal antibody developed as a biosimilar to infliximab (Remicade ® , Janssen). The pharmacokinetic characteristics of CMAB008 and Remicade ® in healthy subjects and patients with moderately to severely active rheumatoid arthritis (RA) were investigated using a populati...